Zepbound vs Mounjaro (April 2026): Same Drug, Different Labels — Which Is Right for You?

Zepbound and Mounjaro are the same drug — tirzepatide — sold under different brand names for different FDA-approved uses. Mounjaro was approved by the FDA in May 2022 for Type 2 diabetes. Zepbound was approved November 2023 for chronic weight management and December 2024 for obstructive sleep apnea — the first drug ever approved for OSA. Same molecule, same doses (2.5 mg to 15 mg weekly), same side effects, same manufacturer (Eli Lilly). List price is roughly $1,087/month for both. With commercial insurance and manufacturer savings cards, both drop to $25/month (max $1,950/year).

Quick answer by situation: Have Type 2 diabetes → Mounjaro is the FDA-labeled drug your insurance will cover. Have obesity or BMI 27+ with a weight-related condition → Zepbound is the FDA-labeled drug your insurance will cover. Paying cash → Zepbound wins because LillyDirect sells single-dose vials at $299-$449/mo; Mounjaro does not have an equivalent self-pay vial program. Have both conditions → your provider picks one based on your primary diagnosis and your insurance formulary. For compounded alternatives at $99-$199/mo, see our cheapest tirzepatide guide.

Why Same Drug, Different Names

Tirzepatide is a once-weekly injectable peptide developed by Eli Lilly. It's the first medication to activate both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors — a dual-agonist design that distinguishes it from older GLP-1-only drugs like semaglutide (sold as Ozempic, Wegovy, and Rybelsus). For a deeper look at the two drug classes, see our semaglutide vs tirzepatide comparison.

Lilly filed two separate New Drug Applications with the FDA: one for tirzepatide as a Type 2 diabetes treatment (branded Mounjaro) and one for tirzepatide as a chronic weight management treatment (branded Zepbound). Each application required its own dedicated clinical trial program — SURPASS-1 through SURPASS-5 for diabetes and SURMOUNT-1 through SURMOUNT-5 for obesity. The FDA evaluates each application independently. Even though the molecule is the same, the two products are legally distinct.

This separation is how the US pharmaceutical system works. Brand identity follows indication. The same pattern applies to other drugs: bupropion is sold as Wellbutrin for depression and Zyban for smoking cessation. Finasteride is sold as Proscar (5 mg, prostate) and Propecia (1 mg, hair loss). Tirzepatide simply has two labels — diabetes and weight/OSA.

FDA Approval Timeline

Tirzepatide has three FDA approvals across two brand names:

• •May 13, 2022 — Mounjaro approved for Type 2 diabetes. Indication: adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus. Approval based on the SURPASS clinical trial program, which showed tirzepatide 15 mg lowered A1C by ~2.0-2.5 percentage points with average weight loss of ~10-12% as a secondary outcome.
• •November 8, 2023 — Zepbound approved for chronic weight management. Indication: adjunct to a reduced-calorie diet and increased physical activity for long-term weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Approval based on the SURMOUNT-1 trial showing 20.9% average weight loss at the 15 mg dose over 72 weeks.
• •December 20, 2024 — Zepbound approved for obstructive sleep apnea. Indication: moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity — the first drug ever approved for OSA. Approval based on the SURMOUNT-OSA trial, which showed tirzepatide reduced apnea-hypopnea index (the standard measure of OSA severity) substantially compared to placebo. This is a Zepbound-only indication; Mounjaro's label does not include OSA.

The Mounjaro label covers only Type 2 diabetes. The Zepbound label covers chronic weight management AND obstructive sleep apnea. A patient with obesity and sleep apnea would be prescribed Zepbound under its OSA indication, which may open insurance coverage pathways that weight-loss-only coverage doesn't.

Pricing in April 2026

List price for both medications is approximately $1,087/month, but the actual price most patients pay is dramatically lower through insurance or manufacturer programs. The key differences:

The biggest cash-pay difference: Zepbound has LillyDirect single-dose vials at $299-$449/month, saving $650-$800/month vs the list price. Mounjaro does not have an equivalent self-pay vial program — Mounjaro patients without commercial insurance pay the pen price ($499/mo via Mounjaro Savings Card) or the full list price. For self-paying patients, Zepbound is meaningfully cheaper.

For Medicare beneficiaries, the GLP-1 Bridge program launches July 1, 2026 and covers Zepbound at $50/month for eligible enrollees — the first time Medicare has ever covered a GLP-1 for weight management. Mounjaro has been covered under Medicare Part D for Type 2 diabetes since its 2022 approval.

Insurance Coverage — The Real Difference

Insurance companies cover drugs by FDA-approved indication, not by molecular identity. Your insurance plan has a formulary (list of covered drugs) and prior authorization criteria tied to specific diagnoses. This is where Mounjaro and Zepbound diverge sharply:

• •Commercial insurance — Type 2 diabetes: Mounjaro is covered by most commercial plans under the diabetes benefit. Zepbound is not covered for diabetes; attempting to fill Zepbound with a diabetes diagnosis will typically be denied.
• •Commercial insurance — obesity/weight management: Zepbound is covered by plans that include weight-management benefits (roughly 50-60% of commercial plans as of 2026). Mounjaro is not covered for weight loss; attempting to fill Mounjaro with an obesity-only diagnosis will typically be denied.
• •Commercial insurance — obstructive sleep apnea: Zepbound's OSA indication can expand coverage to plans that exclude weight-management but cover OSA treatments. This is Zepbound's biggest insurance advantage over Mounjaro.
• •Medicare Part D — diabetes: Mounjaro covered since 2022. Zepbound not covered under a diabetes indication.
• •Medicare Part D — obesity: Neither was covered until July 2026, when the GLP-1 Bridge program launches, covering Zepbound at $50/month for eligible beneficiaries.
• •Medicaid: Coverage varies by state. Mounjaro is covered in most states for Type 2 diabetes. Zepbound coverage for weight loss is more limited — see our state-by-state Medicaid GLP-1 coverage map.
• •Prior authorization: Required by most insurers for both. Typical criteria for Zepbound: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease). Typical criteria for Mounjaro: diagnosed Type 2 diabetes with A1C above target despite other medications.

Dosing Is Identical

Because Mounjaro and Zepbound are the same molecule, they share the exact same dose titration schedule. Both are once-weekly subcutaneous injections with the same starter dose, escalation path, and maximum dose:

The manufacturer recommends each dose be maintained for at least 4 weeks before escalation to reduce GI side effects. Most providers reach the 5 mg or 10 mg maintenance dose by month 3-5, then hold or escalate based on response. The 12.5 mg and 15 mg doses are typically reserved for patients who haven't reached their treatment goal at lower doses.

Side Effects Are Identical

Because the molecule is identical, the side effect profile is identical. GI side effects dominate — nausea, diarrhea, vomiting, and constipation are most common and peak during dose escalation. Rates from the Zepbound prescribing information and SURMOUNT trials:

For a full breakdown of side effects, management strategies, and when to call your doctor, see our Zepbound side effects guide. Both medications carry the same FDA boxed warning about thyroid C-cell tumors (based on animal studies) and the same contraindications for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Who Should Get Mounjaro

• •You have Type 2 diabetes and need glycemic control — this is the FDA-labeled indication and covered by most commercial insurance and Medicare Part D
• •You have both Type 2 diabetes and obesity, and your provider uses the diabetes indication for coverage — Mounjaro will address both A1C and weight
• •Your commercial insurance formulary prefers Mounjaro over other diabetes medications (formulary preferences vary by plan)
• •You're stable on Ozempic or Trulicity and want to switch to a dual GIP/GLP-1 agonist for better A1C control or additional weight loss benefit

Who Should Get Zepbound

• •Your primary diagnosis is obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition — this is the FDA-labeled indication
• •You have moderate-to-severe obstructive sleep apnea with obesity — Zepbound is the only tirzepatide product approved for OSA, and this indication can expand insurance coverage
• •You're paying out-of-pocket and want the lowest price — LillyDirect single-dose vials at $299-$449/month are significantly cheaper than Mounjaro's self-pay pen price of $499/month
• •You're a Medicare beneficiary starting July 2026 — the GLP-1 Bridge program covers Zepbound at $50/month for eligible enrollees
• •Your commercial insurance covers weight-management medications and includes Zepbound on its formulary

What About Off-Label Use?

Off-label prescribing — using an FDA-approved drug for a condition not listed on its label — is legal in the US and common in medical practice. Before Zepbound was approved in November 2023, providers routinely prescribed Mounjaro off-label for weight loss, and patients with commercial insurance sometimes got coverage through weight-management benefits. After Zepbound's approval, off-label Mounjaro for weight loss became less defensible because an FDA-labeled alternative exists.

Important practical consequences of off-label prescribing for tirzepatide in 2026:

• •Insurance denial is likely: Commercial insurers and Medicare Part D typically deny claims when the diagnosis code doesn't match the FDA label. Mounjaro billed to a weight-loss-only diagnosis will usually be denied.
• •Savings cards may not apply: Lilly's Mounjaro Savings Card requires patients to have a Type 2 diabetes diagnosis on file; using the card for weight loss may violate the savings card terms.
• •Prior authorization becomes harder: Prior auth committees check the diagnosis against the drug label. Off-label combinations get flagged and often require appeals.
• •Your provider bears added liability: If an off-label prescription leads to a bad outcome, the prescriber's defense is weaker than for an on-label prescription.

Switching Between Mounjaro and Zepbound

Switching between Mounjaro and Zepbound is essentially switching the label on the same drug, so there's no pharmacological transition period. Most providers maintain the same dose during a switch. For example, a patient stable on Mounjaro 10 mg who switches to Zepbound continues at Zepbound 10 mg with no washout or re-titration.

The most common reasons for switching:

• •Diagnosis shift — a Mounjaro patient develops significant weight loss goals, or a Zepbound patient is diagnosed with Type 2 diabetes
• •Insurance formulary change — an employer plan switches preferred tirzepatide brand mid-year
• •Self-pay access — a cash-paying Mounjaro patient switches to Zepbound to access LillyDirect self-pay vials at lower cost
• •Medicare enrollment — a Mounjaro patient ages into Medicare and switches to Zepbound via the GLP-1 Bridge program (after July 2026)

If you're considering a switch, the decision should be made with your prescriber. Telehealth platforms like Eden Health, Hers, and Enhance MD can prescribe either brand or compounded tirzepatide alternatives depending on your situation. Compare cost and clinical support across providers using our cost calculator or take the match quiz for a personalized recommendation.

Our Recommendation

If you have Type 2 diabetes and your primary goal is blood sugar control, Mounjaro is the correct labeled drug and will get the easiest insurance approval. Weight loss is a common secondary benefit — the SURPASS trials showed patients on Mounjaro 15 mg lost 10-12% of body weight even when the trial was designed to evaluate diabetes outcomes.

If you have obesity, overweight with a comorbid condition, or moderate-to-severe sleep apnea, Zepbound is the correct labeled drug. For cash-paying patients, Zepbound is meaningfully cheaper through LillyDirect vials ($299-$449/mo) compared to Mounjaro's self-pay pricing. If Wegovy is covered by your insurance and Zepbound isn't, that's the pragmatic choice — Wegovy produces slightly less weight loss on average but is often the alternative when tirzepatide coverage is denied.

If you have both conditions, ask your provider which diagnosis code to bill and what coverage differences that creates. Many patients end up on Zepbound because the weight-management indication covers their metabolic health holistically and (post-July 2026) Medicare enrollees have GLP-1 Bridge access to it at $50/month.

For the cheapest paths to tirzepatide — including compounded alternatives through telehealth platforms — see our cheapest tirzepatide providers guide or take the match quiz for a personalized recommendation based on your budget, insurance, and goals.

FAQ

Are Zepbound and Mounjaro actually the same drug? Yes. Both contain tirzepatide as the sole active ingredient at the same doses (2.5 to 15 mg). The formulation, injection device, and manufacturer (Eli Lilly) are identical. The only difference is the brand name, which tracks the FDA-approved indication.

Is Zepbound better for weight loss than Mounjaro? The molecule is identical, so the weight loss effect is identical. SURMOUNT-1 showed 20.9% body weight loss at 72 weeks on tirzepatide 15 mg. That result applies to Mounjaro 15 mg and Zepbound 15 mg equally — the difference is only the FDA label and insurance coverage.

Can I use my Mounjaro Savings Card for Zepbound? No. The cards are separate programs with separate eligibility. The Mounjaro Savings Card requires a Type 2 diabetes diagnosis. The Zepbound Savings Card requires a weight management or OSA prescription. If you switch drugs, apply for the appropriate card.

Which one is cheaper if I'm paying cash? Zepbound — by a meaningful margin. Zepbound vials through LillyDirect cost $299 (2.5 mg starter) to $449 (7.5-15 mg maintenance) per month. Mounjaro does not have an equivalent self-pay vial program; cash-paying Mounjaro patients pay $499/month through the savings card or the full list price.

Will Medicare cover Zepbound or Mounjaro in 2026? Mounjaro is covered under Medicare Part D for Type 2 diabetes (since 2022). Neither was covered for weight loss until July 1, 2026, when the GLP-1 Bridge program launches and covers Zepbound at $50/month for eligible beneficiaries. See our Medicare Part D GLP-1 coverage guide for full details.

Is compounded tirzepatide the same as Zepbound or Mounjaro? Chemically similar but not identical and not FDA-approved as Zepbound or Mounjaro. Compounded tirzepatide is made by 503A compounding pharmacies — not by Eli Lilly — and costs $99-$199/month at telehealth platforms. FDA enforcement on compounded GLP-1s has tightened since tirzepatide was removed from the shortage list. See compounded tirzepatide for current status.

Sources

• •FDA Approves Lilly's Mounjaro (tirzepatide) Injection — Eli Lilly press release, May 13, 2022
• •FDA Approves New Medication for Chronic Weight Management — FDA press release, Zepbound approval, November 8, 2023
• •FDA Approves Zepbound for Obstructive Sleep Apnea — Eli Lilly press release, December 20, 2024
• •SURMOUNT-1 Trial Results (NEJM) — Zepbound obesity trial, 20.9% weight loss at 72 weeks
• •SURPASS-2 Trial Results (NEJM) — Mounjaro vs semaglutide head-to-head in Type 2 diabetes
• •SURMOUNT-OSA Trial Results (NEJM) — Zepbound for obstructive sleep apnea
• •Zepbound prescribing information — FDA label, current version
• •Mounjaro Cost Information — Eli Lilly 2026 pricing
• •Mounjaro Savings Resources — Eli Lilly savings card program
• •CMS GLP-1 Bridge Program — Medicare Part D expansion, July 2026

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Tirzepatide is a prescription medication with FDA boxed warnings for thyroid C-cell tumors and contraindications including personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Never start, stop, or switch a GLP-1 medication without consultation with a licensed healthcare provider. Pricing information reflects publicly available manufacturer and payer data as of April 2026 and may change.